Chimeric Therapeutics Ltd: Achieve Clinics collaboration to expand reach of CHM CDH17
Chimeric Therapeutics Ltd: University of Pennsylvania joins CHM CDH17 Phase 1/2 trial
Chimeric Therapeutics Ltd: First patient dosed in Phase 1/2 trial of CHM CDH17
Chimeric Therapeutics Ltd: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete
Chimeric Therapeutics Ltd: Chimeric receives $1.5 M advance on FY24 R&D tax incentive
Chimeric Therapeutics Ltd: Chimeric partnering with Cell Therapies Australia
Chimeric Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Chimeric Therapeutics Ltd: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
Chimeric Therapeutics Ltd: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
Chimeric Therapeutics Ltd: Final Director's Interest Notice
Chimeric Therapeutics Ltd: Chimeric opens CHM CDH17 Phase 1/2 trial
Chimeric Therapeutics Ltd: CHM CDH17 Phase 1/2 clinical trial approved for initiation
Chimeric Therapeutics Ltd: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
Chimeric Therapeutics Ltd: Dr Rebecca McQualter appointed COO
Chimeric Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Chimeric Therapeutics Ltd: Change of Director's Interest Notice PH
Chimeric Therapeutics Ltd: Change of Director's Interest Notice PH
Chimeric Therapeutics Ltd: US patent allowed for CHM 0201 (CORE-NK) technology
Chimeric Therapeutics Ltd: Chimeric to present at NWR Virtual Healthcare Conference
Chimeric Therapeutics Ltd: Clinical milestones for 2024 & 2023 successes highlighted
No Data
No Data